动物造模,高尿酸血症 z-bio 2023-02-27 518

　　Objective: To establish acute mouse and chronic rat hyperuricemia models, and use positive drugs to verify the curability of the two models, so as to provide model tools for the development of anti-hyperuric acid drugs.

　　Methods: Acute gout model mice were established by intraperitoneal injection of hypoxanthine combined with subcutaneous injection of potassium oxonate. The positive group was given allopurinol tablets half an hour after modeling, and serum uric acid, serum creatinine and serum uric acid were measured 2 hours after modeling. Urea nitrogen and hepatic xanthine oxidase (XOD) activity. Rats with chronic gout were given adenine and ethambutol hydrochloride by gavage every day to establish a model, and the positive group was given allopurinol tablets every day. After 21 consecutive days, serum uric acid, serum creatinine, serum urea nitrogen, liver XOD activity were detected, and renal tissue disease was detected. Physical examination.

　　Results: Serum uric acid and serum creatinine were significantly increased in both acute and chronic gout model animals (P<0.05). Serum urea nitrogen and liver XOD activity were also significantly increased in chronic gout rats (P<0.05). and urate crystals aggravated, and the score increased significantly (P<0.05). The positive drug allopurinol can significantly reduce the serum uric acid value of acute and chronic hyperuric acid animals, reduce the serum creatinine value and liver XOD activity of chronic hyperuric acid animals, improve kidney damage and reduce urate crystals (P<0.05).

　　Conclusion: The method used in this experiment is suitable for establishing animal models of acute and chronic hyperuricemia, and can be used for drug pharmacodynamics observation.